双特异性抗体治疗小细胞肺癌的实验研究  

Treatment of Small Cell Lung Cancer with Bispecific Antibody

作　　者：肖琅[1] 杨春红[1] 刘迎午[1] 朱争艳[1] 吴鸿燕[1] 杜建民[1] 

机构地区：[1]天津市第三中心医院,300170

出　　处：《实用癌症杂志》2002年第3期244-247,共4页The Practical Journal of Cancer

基　　金：天津市卫生局科研基金资助 (No :97KY GG2 )

摘　　要：目的　探讨双特异性抗体在小细胞肺癌免疫治疗中的应用价值。方法　制备既抗小细胞肺癌表面抗原又抗T细胞表面CD 3抗原的双特异抗体 (简称双抗 ,BSAb) ,分别进行体外实验及动物实验。结果　体外实验显示 ,加入双抗的较未加入双抗的LAK细胞对小细胞肺癌细胞杀伤活性明显提高 (P <0 .0 5 )。显示杀伤活性与效靶比例呈正相关。在肿瘤生长的动物实验中 ,接种后第 7～ 10天双抗组肿瘤发生率明显低于未用双抗组 (P <0 .0 5 ) ;裸鼠生存动物实验中 ,双抗组平均存活为 5 8.4天 ,是对照组的 1.5倍。结论　双特异性抗体能提高LAK细胞对小细胞肺癌的治疗效果。Objective To evaluate the effect of bispecific antibodies(BsAbs) on treatment of small cell lung cancer.Methods A BsAb with anti CD3 and antitumor associated antigen was used to target on human peripheral blood lymphocytes(PBL) against small cell lung cancer cells,in vitro as well as in animal model.Results In vitro study,the results of 51 Cr release assay demonstrated that BsAb could result in concentration dependent enhancement effects on the cytotoxicity of activated LAK cell against small cell lung cancer cells on day and treated with ip/ie injection of activated PBL coated with the bispecific antibodies(anti CD3×antitumor),using an approximate effect∶target ratio of 3∶1.Treatment was evaluated for the ability either to inhibit tumor growth at the 10th day or to prolong survival of the tumor bearing mice.The mean survival time of the tumor bearing mice treated with BsAb coated PBL was 58.4 days,1.5 times that of untreated mice.Conclusion The treatment with bispecific antibody(anti CD 3×antitumor) may be beneficial for small cell lung cancer.

关 键 词：双特异性抗体 治疗 小细胞肺癌 实验研究 LAK细胞 

分 类 号：R734.2[医药卫生—肿瘤] R730.51[医药卫生—临床医学]